{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:49:38Z","timestamp":1783010978345,"version":"3.54.6"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSCO"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with cancer should appropriately receive antiemetic therapies against chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an important role in managing CINV. Accordingly, the first Japanese antiemetic guideline published in 2010 by the Japan Society of Clinical Oncology (JSCO) has considerably aided Japanese medical staff in providing antiemetic therapies across chemotherapy clinics. With the yearly advancements in antiemetic therapies, the Japanese antiemetic guidelines require revisions according to published evidence regarding antiemetic management worldwide. A revised version of the first antiemetic guideline that considered several upcoming evidences had been published online in 2014 (version 1.2), in which several updated descriptions were included. The 2015 JSCO clinical practice guideline for antiemesis (version 2.0) (in Japanese) has addressed clinical antiemetic concerns and includes four major revisions regarding (1) changes in emetogenic risk categorization for anti-cancer agents, (2) olanzapine usage as an antiemetic drug, (3) the steroid-sparing method, and (4) adverse drug reactions of antiemetic agents. We herein present an English update summary for the 2015 JSCO clinical practice guideline for antiemesis (version 2.0).<\/jats:p>","DOI":"10.1007\/s10147-020-01818-3","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T09:07:07Z","timestamp":1604826427000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 \u00a0Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis"],"prefix":"10.1007","volume":"26","author":[{"given":"Kenjiro","family":"Aogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-9519","authenticated-orcid":false,"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eijiro","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Nishidate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,8]]},"reference":[{"key":"1818_CR1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081\u20131090","journal-title":"Ann Oncol"},{"key":"1818_CR2","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2007.15.9533","volume":"26","author":"A Naeim","year":"2008","unstructured":"Naeim A, Dy SM, Lorenz KA et al (2008) Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 26:3903\u20133910","journal-title":"J Clin Oncol"},{"key":"1818_CR3","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482\u20132494","journal-title":"N Engl J Med"},{"key":"1818_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology-Antiemesis-ver. 1, 2015"},{"key":"1818_CR5","unstructured":"MASCC\/ESMO-Antiemetic Guidelines 2013"},{"key":"1818_CR6","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"Antiemetics","year":"2011","unstructured":"Antiemetics (2011) American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"key":"1818_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","volume":"21","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1\u201312","journal-title":"Int J Clin Oncol"},{"key":"1818_CR8","first-page":"305","volume":"42","author":"T Saeki","year":"2015","unstructured":"Saeki T, Tamura K, Aiba K et al (2015) The survey for anti-emetic guideline by using questioner. Gan To Kagaku Ryoho 42:305\u2013311","journal-title":"Gan To Kagaku Ryoho"},{"key":"1818_CR9","unstructured":"https:\/\/www.jsco-cpg.jp\/item\/29\/index.html(in Japanese)"},{"key":"1818_CR10","unstructured":"The Cochrane library. https:\/\/www.cochranelibrary.com\/"},{"key":"1818_CR11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jjco\/hyu191","volume":"45","author":"K Nagashima","year":"2015","unstructured":"Nagashima K, Iwasa S, Yanai T et al (2015) A double-blind randomized phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy. Jpn J Clin Oncol 45:229\u2013231","journal-title":"Jpn J Clin Oncol"},{"key":"1818_CR12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663","journal-title":"Support Care Cancer"},{"key":"1818_CR13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","volume":"13","author":"RM Navari","year":"2005","unstructured":"Navari RM, Einhorn LH, Passik SD et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529\u2013534","journal-title":"Support Care Cancer"},{"key":"1818_CR14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15:1285\u20131291","journal-title":"Support Care Cancer"},{"key":"1818_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X et al (2009) Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131\u2013138","journal-title":"J Exp Clin Cancer Res"},{"key":"1818_CR16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"1818_CR17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M, Fabi A, Nol\u00e8 F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088","journal-title":"Ann Oncol"},{"key":"1818_CR18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A et al (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217\u20131225","journal-title":"Support Care Cancer"},{"key":"1818_CR19","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2011.39.8123","volume":"30","author":"JA Roscoe","year":"2012","unstructured":"Roscoe JA, Heckler CE, Morrow GR et al (2012) Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30:3389\u20133395","journal-title":"J Clin Oncol"},{"key":"1818_CR20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2015","unstructured":"Komatsu Y, Okita K, Yuki S et al (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 106:891\u2013895","journal-title":"Cancer Sci"},{"key":"1818_CR21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<144::AID-CNCR20>3.0.CO;2-Z","volume":"78","author":"DS Ettinger","year":"1996","unstructured":"Ettinger DS, Eisenberg PD, Fitts D et al (1996) A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 78:144\u20131451","journal-title":"Cancer"},{"key":"1818_CR22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","volume":"97","author":"SP Chawla","year":"2003","unstructured":"Chawla SP, Grunberg SM, Gralla RJ et al (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting. Cancer 97:2290\u20132300","journal-title":"Cancer"},{"key":"1818_CR23","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003a) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1818_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2003.08.028","volume":"40","author":"R de Wit","year":"2004","unstructured":"de Wit R, Herrstedt J, Rapoport B et al (2004) The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebocontrolled phase III clinical trials. Eur J Cancer 40:403\u2013410","journal-title":"Eur J Cancer"},{"key":"1818_CR25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2013EASE. J Clin Oncol 29:1495\u20131501","journal-title":"J Clin Oncol"},{"key":"1818_CR26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441\u20131449","journal-title":"Ann Oncol"},{"key":"1818_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124","journal-title":"Lancet Oncol"},{"key":"1818_CR28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","volume":"51","author":"J Nishimura","year":"2015","unstructured":"Nishimura J, Satoh T, Fukunaga M et al (2015) Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274\u20131282","journal-title":"Eur J Cancer"},{"key":"1818_CR29","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003b) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1818_CR30","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003a) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo controlled trial in Latin America. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"1818_CR31","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in the patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830","journal-title":"J Clin Oncol"},{"key":"1818_CR32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/jnci\/89.11.817","volume":"89","author":"MG Kris","year":"1997","unstructured":"Kris MG, Radford JE, Pizzo BA et al (1997) Use of a NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 89:817\u2013818","journal-title":"J Natl Cancer Inst"},{"key":"1818_CR33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000\u20131006","journal-title":"Ann Oncol"},{"key":"1818_CR34","doi-asserted-by":"crossref","unstructured":"Hashimoto H, Yamanaka T, Shimada Y et al (2013) Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial. J Clin Oncol 31(supple; abstr 9621)","DOI":"10.1200\/jco.2013.31.15_suppl.9621"},{"key":"1818_CR35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"1818_CR36","doi-asserted-by":"crossref","unstructured":"Matsumoto K, Takahashi M, Sato K et al (2015) Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. J Clin Oncol 33(supple; abstr 9598)","DOI":"10.1200\/jco.2015.33.15_suppl.9598"},{"key":"1818_CR37","doi-asserted-by":"crossref","unstructured":"Matsumoto K, Takahashi M, Sato K et al (2020) A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med. (Epub ahead of print)","DOI":"10.1002\/cam4.2979"},{"key":"1818_CR38","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1056\/NEJM200005253422102","volume":"342","author":"The Italian Group for Antiemetic Research","year":"2000","unstructured":"The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554\u20131559","journal-title":"N Engl J Med"},{"key":"1818_CR39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.annonc.a010483","volume":"7","author":"WH Koo","year":"1996","unstructured":"Koo WH, Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71\u201374","journal-title":"Ann Oncol"},{"key":"1818_CR40","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO.2005.04.022","volume":"23","author":"O Geling","year":"2005","unstructured":"Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289\u20131294","journal-title":"J Clin Oncol"},{"key":"1818_CR41","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","volume":"98","author":"P Eisenberg","year":"2003","unstructured":"Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473\u20132482","journal-title":"Cancer"},{"key":"1818_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.coc.0000145983.35929.2a","volume":"28","author":"C Lindley","year":"2005","unstructured":"Lindley C, Goodin S, McCune J et al (2005) Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28:270\u2013276","journal-title":"Am J Clin Oncol"},{"key":"1818_CR43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423\u2013431","journal-title":"Support Care Cancer"},{"key":"1818_CR44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00258206","volume":"7","author":"MS Aapro","year":"1981","unstructured":"Aapro MS, Alberts DS (1981) High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 7:11\u201314","journal-title":"Cancer Chemother Pharmacol"},{"key":"1818_CR45","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","volume":"18","author":"JP Ioannidis","year":"2000","unstructured":"Ioannidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control chemotherapy-induced nausea and vomiting; a meta-analysis of randomized evidence. J Clin Oncol 18:3409\u20133422","journal-title":"J Clin Oncol"},{"key":"1818_CR46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg SM (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 18:233\u2013240","journal-title":"Ann Oncol"},{"key":"1818_CR47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/bjc.1997.341","volume":"76","author":"S Sekine","year":"1997","unstructured":"Sekine S, Nishiwaki Y, Kakinuma R et al (1997) Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis JCOG study 9413. Br J Cancer 76:90\u201392","journal-title":"Br J Cancer"},{"key":"1818_CR48","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00520-004-0629-y","volume":"12","author":"P Glare","year":"2004","unstructured":"Glare P, Pereira G, Kristjanson LJ et al (2004) Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432\u2013440","journal-title":"Support Care Cancer"},{"key":"1818_CR49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1089\/jpm.2011.0058","volume":"14","author":"JM Jones","year":"2011","unstructured":"Jones JM, Qin R, Bardia A et al (2011) Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med 14:810\u2013814","journal-title":"J Palliat Med"},{"key":"1818_CR50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2007.0004","volume":"5","author":"DS Ettinger","year":"2007","unstructured":"Ettinger DS, Bierman PJ, Bradbury B et al (2007) National comprehensive Cancer Network (NCCN). J Natl Compr Cancer Netw 5:12\u201333","journal-title":"J Natl Compr Cancer Netw"},{"key":"1818_CR51","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"JW Valle","year":"2010","unstructured":"Valle JW, Wasan HS, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"1818_CR52","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","volume":"316","author":"SD Williams","year":"1987","unstructured":"Williams SD, Birch R, Einhorn LH et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435\u20131440","journal-title":"N Engl J Med"},{"key":"1818_CR53","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJM198212093072402","volume":"307","author":"GR Morrow","year":"1982","unstructured":"Morrow GR, Morrel C (1982) Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 307:1476\u20131480","journal-title":"N Engl J Med"},{"key":"1818_CR54","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0885-3924(91)90011-R","volume":"6","author":"GR Morrow","year":"1991","unstructured":"Morrow GR, Lindke J, Black PM et al (1991) Predicting development of anticipatory nausea in cancer patients: prospective examination of right clinical characteristics. J Pain Sympt Manag 6:215\u2013223","journal-title":"J Pain Sympt Manag"},{"key":"1818_CR55","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/1097-0142(19881215)62:12<2607::AID-CNCR2820621226>3.0.CO;2-S","volume":"62","author":"MA Andrykowski","year":"1988","unstructured":"Andrykowski MA, Jacobsen PB, Marks E et al (1988) Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607\u20132613","journal-title":"Cancer"},{"key":"1818_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000226675","volume":"46","author":"E Alba","year":"1989","unstructured":"Alba E, Bastus R, de Andres L et al (1989) Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology 46:26\u201330","journal-title":"Oncology"},{"key":"1818_CR57","first-page":"585","volume":"68","author":"GR Morrow","year":"1982","unstructured":"Morrow GR (1982) Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68:585\u2013588","journal-title":"J Natl Cancer Inst"},{"key":"1818_CR58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s005200050163","volume":"6","author":"PC Feyer","year":"1998","unstructured":"Feyer PC, Stewart AL, Titlbach OJ et al (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 6:253\u2013260","journal-title":"Support Care Cancer"},{"key":"1818_CR59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bmt.1702479","volume":"26","author":"TR Spitzer","year":"2000","unstructured":"Spitzer TR, Friedman CJ, Bushnell W et al (2000) Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 26:203\u2013210","journal-title":"Bone Marrow Transplant"},{"key":"1818_CR60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/oxfordjournals.annonc.a057871","volume":"2","author":"M Tonato","year":"1991","unstructured":"Tonato M, Rolia F, Del Favero A et al (1991) Methodology of antiemetic trials. Ann Oncol 2:107\u2013114","journal-title":"Ann Oncol"},{"key":"1818_CR61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.1987.5.1.141","volume":"5","author":"F Rolia","year":"1987","unstructured":"Rolia F, Tonato M, Basurto C et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141\u2013149","journal-title":"J Clin Oncol"},{"key":"1818_CR62","first-page":"796","volume":"309","author":"JR Sullivan","year":"1983","unstructured":"Sullivan JR, Leyden MJ, Bell R et al (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796","journal-title":"N Engl J Med"},{"key":"1818_CR63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 11","key":"1818_CR64","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"GA Hawker","year":"2011","unstructured":"Hawker GA, Mian S, Kendzerska T et al (2011) Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 63(Suppl 11):S240\u2013S252","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1818_CR65","first-page":"889","volume":"26","author":"VA Rhodes","year":"1999","unstructured":"Rhodes VA, McDaniel RW (1999) The Index of Nausea, Vomiting, and Retching: a new format of the index of Nausea and Vomiting. Oncol Nurs Forum 26:889\u2013894","journal-title":"Oncol Nurs Forum"},{"key":"1818_CR66","unstructured":"MASCC antiemesis tool (MAT) https:\/\/www.mascc.org\/mat"},{"key":"1818_CR67","first-page":"72","volume":"66","author":"GR Morrow","year":"1992","unstructured":"Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66:72\u201374","journal-title":"Br J Cancer"},{"key":"1818_CR68","first-page":"72","volume":"66","author":"CM Lindley","year":"1992","unstructured":"Lindley CM, Hirsch JD, O\u2019Neill CV et al (1992) Quality of life consequences of chemotherapy\u2014induced emesis. Qual Life Res 66:72\u201374","journal-title":"Qual Life Res"},{"key":"1818_CR69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdh110","volume":"15","author":"A Ihbe-Heffinger","year":"2004","unstructured":"Ihbe-Heffinger A, Ehlken B, Bernard R et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526\u2013536","journal-title":"Ann Oncol"},{"key":"1818_CR70","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3111\/13696998.2013.832257","volume":"16","author":"PJ Miller","year":"2013","unstructured":"Miller PJ, Balu S, Buchner D et al (2013) Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer. J Med Econ 16:1179\u20131189","journal-title":"J Med Econ"},{"key":"1818_CR71","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00520-007-0338-4","volume":"16","author":"SB Hasler","year":"2008","unstructured":"Hasler SB, Hirt A, Luethy AR et al (2008) Safety of ondansetron loading doses in children with cancer. Support Care Cancer 16:469\u2013475","journal-title":"Support Care Cancer"},{"key":"1818_CR72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.arcmed.2008.04.007","volume":"39","author":"AC Sepulveda-Vildosola","year":"2008","unstructured":"Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601\u2013606","journal-title":"Arch Med Res"},{"key":"1818_CR73","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pbc.21811","volume":"52","author":"L Gore","year":"2009","unstructured":"Gore L, Chawla S, Petrilli A et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242\u2013247","journal-title":"Pediatr Blood Cancer"},{"key":"1818_CR74","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","volume":"12","author":"NJ Talley","year":"1998","unstructured":"Talley NJ, Meineche-Schmidt V, Pare P et al (1998) Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials. Aliment Pharmacol Ther 12:1055\u20131065","journal-title":"Aliment Pharmacol Ther"},{"key":"1818_CR75","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6","volume":"89","author":"A del Giglio","year":"2000","unstructured":"del Giglio A, Soares HP, Caparroz C et al (2000) Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 89:2301\u20132308","journal-title":"Cancer"},{"key":"1818_CR76","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17\u201324","journal-title":"Clin Pharmacol Ther"},{"key":"1818_CR77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-005-0907-8","volume":"61","author":"M Depre","year":"2005","unstructured":"Depre M, Van Hecken A, Oeyen M et al (2005) Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61:341\u2013346","journal-title":"Eur J Clin Pharmacol"},{"key":"1818_CR78","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003b) Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3030\u20133038","journal-title":"Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-020-01818-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01818-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T05:30:22Z","timestamp":1609911022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-020-01818-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,8]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01818-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,8]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Aogi Kenjiro received lecture fees from Taiho Pharmaceutical Co., Ltd.\/Ono Pharmaceutical Co., Ltd. and research funding from Chugai Pharmaceutical Co., Ltd. Saeki Toshiaki received lecture fees from Ono Pharmaceutical Co., Ltd.\/Taiho Pharmaceutical Co., Ltd. Tamura Kazuo received lecture fees from SymBio Pharmaceuticals Limited.\/AC Medical Co., Ltd. Nakagawa Kazuhiko received lecture fees from AstraZeneca K.K.\/Astellas Pharma Inc.\/MSD K.K.\/Ono Pharmaceutical Co., Ltd.\/Nippon Boehringer Ingelheim Co., Ltd.\/Novartis Pharma K.K.\/Pfizer Japan Inc.\/Clinical Trial Co., Ltd.\/Medicus Shuppan, Publishers Co., Ltd.\/Care Net, Inc.\/Reno. Medical K.K.\/Kyorin Pharmaceutical Co., Ltd.\/Medical Review Co., Ltd.\/Roche Diagnostics K.K.\/Bayer Yakuhin, Ltd.\/Medical Mobile Communications Co., Ltd.\/3H Clinical Trial Inc.\/Nichi-Iko Pharmaceutical Co., Ltd.\/Takeda Pharmaceutical Co., Ltd.\/Taiho Pharmaceutical Co., Ltd.\/Bristol Myers Squibb Company\/Eli Lilly Japan K.K.\/SymBio Pharmaceuticals Limited.\/Chugai Pharmaceutical Co., Ltd.\/Nanzando Co., Ltd.\/Yodosha Co., LTD.\/Nikkei Business Publications, Inc.\/Daiichi Sankyo Co., Ltd.\/Thermo Fisher Scientific K.K.\/Yomiuri Telecasting Corporation\/Nippon Kayaku Co., Ltd.\/Merck Biopharma Co., Ltd.\/AbbVie Inc. and research funding from MSD K.K.\/A2 Healthcare Corp.\/inVentiv Health Japan\/Astellas Pharma Inc.\/Daiichi Sankyo Co., Ltd.\/Novartis Pharma K.K.\/AbbVie Inc.\/Quintiles Inc.\/IQVIA Services Japan K.K.\/ICON Japan K.K.\/Chugai Pharmaceutical Co., Ltd.\/Takeda Pharmaceutical Co., Ltd.\/EP-CRSU Co., Ltd.\/Oncology Inc.\/Linical Co., Ltd.\/Eli Lilly Japan K.K.\/Co., Ltd.\/Bristol Myers Squibb Company\/Nippon Boehringer Ingelheim Co., Ltd.\/Taiho Pharmaceutical Co., Ltd.\/Japan Inc.\/International Corp.\/SymBio Pharmaceuticals Limited\/Ono Pharmaceutical Co., Ltd.\/Merck Serono Co., Ltd.\/Merck Biopharma Co., Ltd.\/AstraZeneca K.K.\/CMIC Shift Zero K.K.\/Pharmaceutical Co., Ltd.\/Kyowa Hakko Kirin Co., Ltd.\/EPS Corporation.\/Bayer Yakuhin, Ltd.\/Syneos Health.\/EPS International Co., Ltd.\/Pfizer R&D Japan G.K.\/Otsuka Pharmaceutical Co., Ltd. and consulting or advisory fees from Takeda Pharmaceutical Co., Ltd.\/Kyorin Pharmaceutical Co., Ltd.\/Ono Pharmaceutical Co., Ltd.\/Pfizer Japan Inc.\/Eli Lilly Japan K.K. Boku Narikazu received lecture fees from Taiho Pharmaceutical Co., Ltd.\/Ono Pharmaceutical Co., Ltd.\/Bristol-Myers Squibb Company and research funding from Ono Pharmaceutical Co., Ltd.\/Taiho Pharmaceutical Co., Ltd.\/Takeda Pharmaceutical Co., Ltd. Iihara Hirotoshi received research funding from Ono Pharmaceutical Co., Ltd. Ohtani Shoichiro received lecture fees from Chugai Pharmaceutical Co., Ltd.\/Eisai Co., Ltd.\/Eli Lilly Japan K.K.\/Pfizer Japan Inc.\/AstraZeneca K.K. Takeda Masayuki received lecture fees from Nippon Boehringer Ingelheim Co., Ltd.\/Chugai Pharmaceutical Co., Ltd.\/AstraZeneca K.K.\/Ono Pharmaceutical Co., Ltd.\/Novartis Pharma K.K. The rest of the authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}